View ValuationThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsBerGenBio 将来の成長Future 基準チェック /06BerGenBioの収益は年間20.2%で減少すると予測されていますが、年間収益は年間71.8%で増加すると予想されています。EPS は年間5.8%で減少すると予想されています。主要情報-20.2%収益成長率-5.76%EPS成長率Biotechs 収益成長25.4%収益成長率71.8%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日15 Feb 2024今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Oct 31Oncoinvent ASA (OB:ONCIN) completed the acquisition of BerGenBio ASA (OB:BGBIO) from Hadean Capital I AS and Hventures Capital I AB, managed by Hadean Ventures and others in a reverse merger transaction.Oncoinvent ASA (OB:ONCIN) agreed to acquire BerGenBio ASA (OB:BGBIO) from Hadean Capital I AS and Hventures Capital I AB, managed by Hadean Ventures and others in a reverse merger transaction for approximately NOK 220 million on June 30, 2025. As part of the deal, NOK 217.47 million shall be paid towards the common equity of BerGenBio ASA. The exchange ratio for the merger is 1.20268049. This is an all-share transaction, the BerGenBio shareholders will receive 25% and Oncoinvent 75% of this merged company. And technically, it's BerGenBio will be the surviving entity, but it will be then we name Oncoinvent. So Oncoinvent will be the name going forward when this is all fully completed. Øystein Soug and Tore Kvam will be appointed as the CEO and CFO of the merged entity respectively. The transaction is subject to approval by regulatory board / committee, approval of offer by acquirer shareholders, approval of offer by target shareholders and approval/consents of lenders/creditors. The expected completion of the transaction is around mid-September 2025. As of September 17, 2025 the Merger will be completed on or about 29 October 2025. ABG Sundal Collier ASA acted as financial advisor for Oncoinvent ASA. Advokatfirmaet Schjødt As acted as legal advisor for Oncoinvent ASA. DNB Carnegie acted as financial advisor for BerGenBio ASA. Advokatfirmaet Thommessen AS acted as legal advisor for BerGenBio ASA. Oncoinvent ASA (OB:ONCIN) completed the acquisition of BerGenBio ASA (OB:BGBIO) from Hadean Capital I AS and Hventures Capital I AB, managed by Hadean Ventures and others in a reverse merger transaction on October 29, 2025.お知らせ • Oct 30BerGenBio ASA, Annual General Meeting, May 20, 2026BerGenBio ASA, Annual General Meeting, May 20, 2026.お知らせ • Jul 01BerGenBio ASA (OB:BGBIO) agreed to acquire Oncoinvent ASA (OB:ONCIN) from Hadean Capital I AS and Hventures Capital I AB, managed by Hadean Ventures and others for NOK 164.2 million.BerGenBio ASA (OB:BGBIO) agreed to acquire Oncoinvent ASA (OB:ONCIN) from Hadean Capital I AS and Hventures Capital I AB, managed by Hadean Ventures and others for NOK 164.2 million on June 30, 2025. Aspart of the consideration, BerGenBio ASA will issue 117.6 million shares to Oncoinvent ASA. The exchange ratio for the merger is 1.20268049. The merged company is expected to be renamed Oncoinvent. Øystein Soug and Tore Kvam will be appointed as the CEO and CFO of the merged entity respectively. The transaction is subject to approval by regulatory board / committee, approval of offer by acquirer shareholders, approval of offer by target shareholders and approval/consents of lenders/creditors. The expected completion of the transaction is around mid-September 2025. ABG Sundal Collier ASA acted as financial advisor for Oncoinvent ASA. Advokatfirmaet Schjødt As acted as legal advisor for Oncoinvent ASA. DNB Carnegie acted as financial advisor for BerGenBio ASA. Advokatfirmaet Thommessen AS acted as legal advisor for BerGenBio ASA.お知らせ • Mar 26BerGenBio ASA Announces Nature Communications Publication of BGBC003 Ph2 Data in Relapsed/Refractory Acute Myeloid Leukemia PatientsBerGenBio ASA announced the publication of a peer-reviewed article entitled "Bemcentinib as Monotherapy and in Combination with Low-Dose Cytarabine in Acute Myeloid Leukemia Patients Unfit for Intensive Chemotherapy" in the journal Nature Communications. The article highlights results in 36 patients treated with a combination of BerGenBio's selective oral AXL inhibitor bemcentinib in combination with low-dose cytarabine (LDAC) chemotherapy. Overall, patients who received the combination had an overall survival of 7.8 months, substantially longer than that expected in this difficult-to-treat patient population.お知らせ • Feb 26BerGenBio ASA Announces Discinuation of 1L STK11M NSCLC Study and Exploration of Strategic AlternativesBerGenBio ASA announced its decision to close its BGBC016 study of bemcentinib in combination with standard of care therapy in first line (1L) non-squamous Non-Small Cell Lung Cancer (NSCLC) patients with a mutation in the STK11 gene (STK11m). In 2024, the company announced the completion of enrollment in the Ph1b portion of the study which demonstrated acceptable safety in 1L NSCLC patients regardless of STK11 mutational status, as evaluated by an independent Data Safety Monitoring Board (DSMB). Early encouraging data were seen in three STK11m patients, including one patient who experienced a complete response and who remains in response and on treatment after nearly two years. The company, in agreement with the independent DSMB, determined that these initial results warranted the continuation of the study into the Ph2a portion. In March 2024, the company initiated the Ph2a portion of the study designed to recruit 40 evaluable 1L STK11m NSCLC patients. The primary endpoint for the Ph2a was overall response rate (ORR). To determine the feasibility of obtaining near-term funding, the company performed a preliminary analysis of the responses in the 10 efficacy evaluable STK11m patients. While there was 1 response in the Ph1b the company did not observe additional responses in the Ph2a patients. Consequently, the company has decided to discontinue the BGBC016 study. The Board of Directors has now initiated an exploration of strategic alternatives. As part of this process, the board will consider a range of options for the company including, among other things, a potential sale, merger, or other strategic transaction. There can be no assurance that this exploration process will result in any transaction.お知らせ • Jan 07Bergenbio Asa Announces First Patient Enters into Advanced Adenocarcinoma Lung Cancer TrialBerGenBio ASA announced that the first patient has been included in a clinical trial sponsored by the Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio). The study is led by Josephine A. Taverna, MD, a thoracic oncologist at the Mays Cancer Center and Associate Professor in the Division of Hematology and Oncology at UT Health San Antonio. The trial is designed to study BerGenBio's bemcentinib in combination with pacritinib, which is a JAK2 inhibitor indicated for treatment of the bone marrow disorder myelofibrosis in patients with platelet counts below 50 x 109/L. It works by blocking certain growth factors and cytokines. Pacritinib is marketed in the United States as VONJO and owned by Swedish Orphan Biovitrum AB (Sobi), a specialized international biopharmaceutical company. Bemcentinib is a first-in-class, selective, oral once-a-day inhibitor of AXL receptor tyrosine kinase, a promising therapeutic target for serious diseases. The study will include patients with lung adenocarcinoma, the most common type of lung cancer in the United States, accounting for approximately 40% of all lung cancers. The study is funded by a grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH).お知らせ • Dec 16BerGenBio ASA, Annual General Meeting, May 20, 2025BerGenBio ASA, Annual General Meeting, May 20, 2025.お知らせ • Dec 14+ 3 more updatesBerGenBio ASA to Report Q4, 2025 Results on Feb 19, 2026BerGenBio ASA announced that they will report Q4, 2025 results on Feb 19, 2026お知らせ • Nov 21BerGenBio ASA Appoints Olav Hellebø as CEO, Effective November 21, 2024BerGenBio ASA announced the appointment of Olav Hellebø as CEO. Mr. Hellebø will assume the position on November 21, 2024. Mr. Hellebø brings three decades of experience in the pharmaceutical and biotechnology industries. Since 2023, he has served as board director in the clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has been a board director at the clinical stage biopharmaceutical company, Antev Ltd, specializing in urology and oncology treatments. Prior to this, Mr. Hellebø's experience includes the role as CEO of ReNeuron Group PLC, a UK-based clinical-stage company specializing in cell therapy for ophthalmic and neurology-related diseases, and CEO at Clavis Pharma ASA, an oncology-focused biotech company traded at the Oslo Stock Exchange. Mr. Hellebø's earlier career includes leadership roles at UCB-Celltech, Novartis UK, and at Schering-Plough (now part of Merck & Co.).お知らせ • Oct 11Martin Olin to Step Down from BerGenBio ASA as CEOBerGenBio ASA announced that CEO, Martin Olin will be leaving the company to pursue other opportunities. Martin will remain in his position during a transition period. The Board of Directors has initiated a succession process and will actively work with the management to support and review the business requirements.お知らせ • Oct 07BerGenBio ASA Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC PatientsBerGenBio ASA announced preliminary safety data from the Phase 1b portion of the BGBC016 study in first-line (1L) Non-Small Cell Lung Cancer (NSCLC) patients. The Phase 1b part of the study evaluated three escalating doses of BerGenBio's selective AXL inhibitor bemcentinib in combination with standard chemo-immunotherapy (CIT), doublet chemotherapy and pembrolizumab, Keytruda, for the 1L treatment of advanced/metastatic NSCLC patients. The primary endpoint was the assessment of the safety profile of the combination in NSCLC patients regardless of their STK11 mutational status. Key conclusions include: All three selected doses demonstrated that the triplet combination is well tolerated with no new safety signals identified, supporting the further clinical development of bemcentinib and CIT in 1L NSCLC patients. No dose-related impact on electrocardiographic changes (QTc), a known class effect of tyrosine kinase inhibitors, was reported for bemcentinib during the observation period. Pharmacokinetic analyses confirmed adequate plasma exposure of bemcentinib, achieving levels consistent with that previously observed in responders in BerGenBio's BGBC008 study of bemcentinib and pembrolizumab in second-line NSCLC patients.お知らせ • Dec 16BerGenBio ASA Announces Closure of EU-Solidact Bemcentinib Study Arm in Hospitalized COVID-19 PatientsBerGenBio ASA announced that the Trial Steering Committee of the EU-SolidAct has recommended to discontinue the bemcentinib study arm in the Ph2b EU-SolidAct platform study in hospitalized COVID-19 patients due to a lack of eligible patients. This recommendation is supported by BerGenBio. The regulatory sponsor of the study, Oslo University Hospital, will enact this decision. In April 2023, BerGenBio announced that the parties unanimously decided to pause the bemcentinib study arm due to a lack of eligible patients. The parties also agreed that a potential resumption of the study arm would be subject to eligible patients being available. BerGenBio will not incur any financial impact from the closure of the bemcentinib study arm.お知らせ • Dec 11BerGenBio ASA Announces Final Bemcentinib Phase 2 Data in AML and MDS Presented at the 2023 ASH MeetingBerGenBio ASA announced that a poster highlighting final results from a Phase 2 clinical study of its highly selective AXL inhibitor bemcentinib in patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) was presented during the 2023 American Society of Hematology (ASH) Annual Meeting being on December 9th in San Diego, CA. The data presented by Professor Sonja Loges, MD, Ph.D. of the University Medical Centre Mannheim, Heidelberg, Germany, showed that bemcentinib was well tolerated in AML and MDS patients. Durable responses were observed across all cohorts with bemcentinib as monotherapy and in combination with chemotherapy. In addition, longitudinal samples analyzed from patients enrolled in the study showed that bemcentinIB inhibited pAXL and downstream markers of activation. This large Phase 2 study included 122 patients in several cohorts of AML and MDS patients treated with bemcentinib monotherapy or in combination with two different chemotherapies.お知らせ • Dec 08BerGenBio ASA has completed a Follow-on Equity Offering in the amount of €240.87 million.BerGenBio ASA has completed a Follow-on Equity Offering in the amount of €240.87 million. Security Name: Shares Security Type: Common Stock Securities Offered: 10,500,000 Price\Range: €22.94 Transaction Features: Subsequent Direct Listingお知らせ • Nov 14+ 4 more updatesBerGenBio ASA to Report Q4, 2024 Results on Feb 19, 2025BerGenBio ASA announced that they will report Q4, 2024 results on Feb 19, 2025お知らせ • Jun 15BerGenBio ASA has completed a Follow-on Equity Offering in the amount of NOK 250 million.BerGenBio ASA has completed a Follow-on Equity Offering in the amount of NOK 250 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,750,000,000 Price\Range: NOK 0.1 Discount Per Security: NOK 0.012 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 750,000,000 Price\Range: NOK 0.1 Transaction Features: Rights Offeringお知らせ • May 10BerGenBio ASA to Report Q1, 2023 Results on Jun 22, 2023BerGenBio ASA announced that they will report Q1, 2023 results at 12:00 PM, Central European Standard Time on Jun 22, 2023お知らせ • Dec 22+ 1 more updateBerGenBio ASA to Report Q4, 2023 Results on Feb 15, 2024BerGenBio ASA announced that they will report Q4, 2023 results on Feb 15, 2024業績と収益の成長予測OTCPK:BRRG.F - アナリストの将来予測と過去の財務データ ( )NOK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2026N/A-329N/AN/A112/31/2025N/A-240N/AN/A112/31/2024N/A-201-203-200212/31/20230-190-225-225N/A9/30/20230-226-281-281N/A6/30/20230-258-282-282N/A3/31/20230-293-289-289N/A12/31/20220-302-288-288N/A9/30/20221-294-290-290N/A6/30/20221-304-294-294N/A3/31/20221-309-307-307N/A12/31/20211-309-303-303N/A9/30/20211-314-280-280N/A6/30/20211-311-280-280N/A3/31/20211-290-246-246N/A12/31/20201-257-234-234N/A9/30/20200-241-216-216N/A6/30/20200-218-187-187N/A3/31/20200-204-190-190N/A12/31/20199-199-187-187N/A9/30/201911-193-186-186N/A6/30/201911-186-189-189N/A3/31/201911-182-201-201N/A12/31/20182-192-187-187N/A9/30/2018N/A-188-180-179N/A6/30/2018N/A-186-178-178N/A3/31/2018N/A-171-143-143N/A12/31/2017N/A-182-168-168N/A9/30/2017N/A-162N/A-164N/A6/30/2017N/A-142N/A-140N/A3/31/2017N/A-175N/A-173N/A12/31/2016N/A-130N/A-124N/A9/30/2016N/A-127N/A-121N/A6/30/2016N/A-128N/A-119N/A3/31/2016N/A-82N/A-71N/A12/31/2015N/A-72N/A-63N/A9/30/2015N/A-70N/A-61N/A6/30/20150-64N/A-59N/A3/31/20151-57N/A-56N/A12/31/20141-58N/A-54N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: BRRG.F今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: BRRG.F今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: BRRG.F今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: BRRG.F来年は収益がないと予測されています。高い収益成長: BRRG.F来年は収益がないと予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: BRRG.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/02/26 18:50終値2023/11/29 00:00収益2023/12/31年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋BerGenBio ASA 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Ulrik TrattnerCarnegie Investment Bank ABGeir HolomDNB CarnegieSean ConroyEdison Investment Research
お知らせ • Oct 31Oncoinvent ASA (OB:ONCIN) completed the acquisition of BerGenBio ASA (OB:BGBIO) from Hadean Capital I AS and Hventures Capital I AB, managed by Hadean Ventures and others in a reverse merger transaction.Oncoinvent ASA (OB:ONCIN) agreed to acquire BerGenBio ASA (OB:BGBIO) from Hadean Capital I AS and Hventures Capital I AB, managed by Hadean Ventures and others in a reverse merger transaction for approximately NOK 220 million on June 30, 2025. As part of the deal, NOK 217.47 million shall be paid towards the common equity of BerGenBio ASA. The exchange ratio for the merger is 1.20268049. This is an all-share transaction, the BerGenBio shareholders will receive 25% and Oncoinvent 75% of this merged company. And technically, it's BerGenBio will be the surviving entity, but it will be then we name Oncoinvent. So Oncoinvent will be the name going forward when this is all fully completed. Øystein Soug and Tore Kvam will be appointed as the CEO and CFO of the merged entity respectively. The transaction is subject to approval by regulatory board / committee, approval of offer by acquirer shareholders, approval of offer by target shareholders and approval/consents of lenders/creditors. The expected completion of the transaction is around mid-September 2025. As of September 17, 2025 the Merger will be completed on or about 29 October 2025. ABG Sundal Collier ASA acted as financial advisor for Oncoinvent ASA. Advokatfirmaet Schjødt As acted as legal advisor for Oncoinvent ASA. DNB Carnegie acted as financial advisor for BerGenBio ASA. Advokatfirmaet Thommessen AS acted as legal advisor for BerGenBio ASA. Oncoinvent ASA (OB:ONCIN) completed the acquisition of BerGenBio ASA (OB:BGBIO) from Hadean Capital I AS and Hventures Capital I AB, managed by Hadean Ventures and others in a reverse merger transaction on October 29, 2025.
お知らせ • Oct 30BerGenBio ASA, Annual General Meeting, May 20, 2026BerGenBio ASA, Annual General Meeting, May 20, 2026.
お知らせ • Jul 01BerGenBio ASA (OB:BGBIO) agreed to acquire Oncoinvent ASA (OB:ONCIN) from Hadean Capital I AS and Hventures Capital I AB, managed by Hadean Ventures and others for NOK 164.2 million.BerGenBio ASA (OB:BGBIO) agreed to acquire Oncoinvent ASA (OB:ONCIN) from Hadean Capital I AS and Hventures Capital I AB, managed by Hadean Ventures and others for NOK 164.2 million on June 30, 2025. Aspart of the consideration, BerGenBio ASA will issue 117.6 million shares to Oncoinvent ASA. The exchange ratio for the merger is 1.20268049. The merged company is expected to be renamed Oncoinvent. Øystein Soug and Tore Kvam will be appointed as the CEO and CFO of the merged entity respectively. The transaction is subject to approval by regulatory board / committee, approval of offer by acquirer shareholders, approval of offer by target shareholders and approval/consents of lenders/creditors. The expected completion of the transaction is around mid-September 2025. ABG Sundal Collier ASA acted as financial advisor for Oncoinvent ASA. Advokatfirmaet Schjødt As acted as legal advisor for Oncoinvent ASA. DNB Carnegie acted as financial advisor for BerGenBio ASA. Advokatfirmaet Thommessen AS acted as legal advisor for BerGenBio ASA.
お知らせ • Mar 26BerGenBio ASA Announces Nature Communications Publication of BGBC003 Ph2 Data in Relapsed/Refractory Acute Myeloid Leukemia PatientsBerGenBio ASA announced the publication of a peer-reviewed article entitled "Bemcentinib as Monotherapy and in Combination with Low-Dose Cytarabine in Acute Myeloid Leukemia Patients Unfit for Intensive Chemotherapy" in the journal Nature Communications. The article highlights results in 36 patients treated with a combination of BerGenBio's selective oral AXL inhibitor bemcentinib in combination with low-dose cytarabine (LDAC) chemotherapy. Overall, patients who received the combination had an overall survival of 7.8 months, substantially longer than that expected in this difficult-to-treat patient population.
お知らせ • Feb 26BerGenBio ASA Announces Discinuation of 1L STK11M NSCLC Study and Exploration of Strategic AlternativesBerGenBio ASA announced its decision to close its BGBC016 study of bemcentinib in combination with standard of care therapy in first line (1L) non-squamous Non-Small Cell Lung Cancer (NSCLC) patients with a mutation in the STK11 gene (STK11m). In 2024, the company announced the completion of enrollment in the Ph1b portion of the study which demonstrated acceptable safety in 1L NSCLC patients regardless of STK11 mutational status, as evaluated by an independent Data Safety Monitoring Board (DSMB). Early encouraging data were seen in three STK11m patients, including one patient who experienced a complete response and who remains in response and on treatment after nearly two years. The company, in agreement with the independent DSMB, determined that these initial results warranted the continuation of the study into the Ph2a portion. In March 2024, the company initiated the Ph2a portion of the study designed to recruit 40 evaluable 1L STK11m NSCLC patients. The primary endpoint for the Ph2a was overall response rate (ORR). To determine the feasibility of obtaining near-term funding, the company performed a preliminary analysis of the responses in the 10 efficacy evaluable STK11m patients. While there was 1 response in the Ph1b the company did not observe additional responses in the Ph2a patients. Consequently, the company has decided to discontinue the BGBC016 study. The Board of Directors has now initiated an exploration of strategic alternatives. As part of this process, the board will consider a range of options for the company including, among other things, a potential sale, merger, or other strategic transaction. There can be no assurance that this exploration process will result in any transaction.
お知らせ • Jan 07Bergenbio Asa Announces First Patient Enters into Advanced Adenocarcinoma Lung Cancer TrialBerGenBio ASA announced that the first patient has been included in a clinical trial sponsored by the Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio). The study is led by Josephine A. Taverna, MD, a thoracic oncologist at the Mays Cancer Center and Associate Professor in the Division of Hematology and Oncology at UT Health San Antonio. The trial is designed to study BerGenBio's bemcentinib in combination with pacritinib, which is a JAK2 inhibitor indicated for treatment of the bone marrow disorder myelofibrosis in patients with platelet counts below 50 x 109/L. It works by blocking certain growth factors and cytokines. Pacritinib is marketed in the United States as VONJO and owned by Swedish Orphan Biovitrum AB (Sobi), a specialized international biopharmaceutical company. Bemcentinib is a first-in-class, selective, oral once-a-day inhibitor of AXL receptor tyrosine kinase, a promising therapeutic target for serious diseases. The study will include patients with lung adenocarcinoma, the most common type of lung cancer in the United States, accounting for approximately 40% of all lung cancers. The study is funded by a grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH).
お知らせ • Dec 16BerGenBio ASA, Annual General Meeting, May 20, 2025BerGenBio ASA, Annual General Meeting, May 20, 2025.
お知らせ • Dec 14+ 3 more updatesBerGenBio ASA to Report Q4, 2025 Results on Feb 19, 2026BerGenBio ASA announced that they will report Q4, 2025 results on Feb 19, 2026
お知らせ • Nov 21BerGenBio ASA Appoints Olav Hellebø as CEO, Effective November 21, 2024BerGenBio ASA announced the appointment of Olav Hellebø as CEO. Mr. Hellebø will assume the position on November 21, 2024. Mr. Hellebø brings three decades of experience in the pharmaceutical and biotechnology industries. Since 2023, he has served as board director in the clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has been a board director at the clinical stage biopharmaceutical company, Antev Ltd, specializing in urology and oncology treatments. Prior to this, Mr. Hellebø's experience includes the role as CEO of ReNeuron Group PLC, a UK-based clinical-stage company specializing in cell therapy for ophthalmic and neurology-related diseases, and CEO at Clavis Pharma ASA, an oncology-focused biotech company traded at the Oslo Stock Exchange. Mr. Hellebø's earlier career includes leadership roles at UCB-Celltech, Novartis UK, and at Schering-Plough (now part of Merck & Co.).
お知らせ • Oct 11Martin Olin to Step Down from BerGenBio ASA as CEOBerGenBio ASA announced that CEO, Martin Olin will be leaving the company to pursue other opportunities. Martin will remain in his position during a transition period. The Board of Directors has initiated a succession process and will actively work with the management to support and review the business requirements.
お知らせ • Oct 07BerGenBio ASA Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC PatientsBerGenBio ASA announced preliminary safety data from the Phase 1b portion of the BGBC016 study in first-line (1L) Non-Small Cell Lung Cancer (NSCLC) patients. The Phase 1b part of the study evaluated three escalating doses of BerGenBio's selective AXL inhibitor bemcentinib in combination with standard chemo-immunotherapy (CIT), doublet chemotherapy and pembrolizumab, Keytruda, for the 1L treatment of advanced/metastatic NSCLC patients. The primary endpoint was the assessment of the safety profile of the combination in NSCLC patients regardless of their STK11 mutational status. Key conclusions include: All three selected doses demonstrated that the triplet combination is well tolerated with no new safety signals identified, supporting the further clinical development of bemcentinib and CIT in 1L NSCLC patients. No dose-related impact on electrocardiographic changes (QTc), a known class effect of tyrosine kinase inhibitors, was reported for bemcentinib during the observation period. Pharmacokinetic analyses confirmed adequate plasma exposure of bemcentinib, achieving levels consistent with that previously observed in responders in BerGenBio's BGBC008 study of bemcentinib and pembrolizumab in second-line NSCLC patients.
お知らせ • Dec 16BerGenBio ASA Announces Closure of EU-Solidact Bemcentinib Study Arm in Hospitalized COVID-19 PatientsBerGenBio ASA announced that the Trial Steering Committee of the EU-SolidAct has recommended to discontinue the bemcentinib study arm in the Ph2b EU-SolidAct platform study in hospitalized COVID-19 patients due to a lack of eligible patients. This recommendation is supported by BerGenBio. The regulatory sponsor of the study, Oslo University Hospital, will enact this decision. In April 2023, BerGenBio announced that the parties unanimously decided to pause the bemcentinib study arm due to a lack of eligible patients. The parties also agreed that a potential resumption of the study arm would be subject to eligible patients being available. BerGenBio will not incur any financial impact from the closure of the bemcentinib study arm.
お知らせ • Dec 11BerGenBio ASA Announces Final Bemcentinib Phase 2 Data in AML and MDS Presented at the 2023 ASH MeetingBerGenBio ASA announced that a poster highlighting final results from a Phase 2 clinical study of its highly selective AXL inhibitor bemcentinib in patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) was presented during the 2023 American Society of Hematology (ASH) Annual Meeting being on December 9th in San Diego, CA. The data presented by Professor Sonja Loges, MD, Ph.D. of the University Medical Centre Mannheim, Heidelberg, Germany, showed that bemcentinib was well tolerated in AML and MDS patients. Durable responses were observed across all cohorts with bemcentinib as monotherapy and in combination with chemotherapy. In addition, longitudinal samples analyzed from patients enrolled in the study showed that bemcentinIB inhibited pAXL and downstream markers of activation. This large Phase 2 study included 122 patients in several cohorts of AML and MDS patients treated with bemcentinib monotherapy or in combination with two different chemotherapies.
お知らせ • Dec 08BerGenBio ASA has completed a Follow-on Equity Offering in the amount of €240.87 million.BerGenBio ASA has completed a Follow-on Equity Offering in the amount of €240.87 million. Security Name: Shares Security Type: Common Stock Securities Offered: 10,500,000 Price\Range: €22.94 Transaction Features: Subsequent Direct Listing
お知らせ • Nov 14+ 4 more updatesBerGenBio ASA to Report Q4, 2024 Results on Feb 19, 2025BerGenBio ASA announced that they will report Q4, 2024 results on Feb 19, 2025
お知らせ • Jun 15BerGenBio ASA has completed a Follow-on Equity Offering in the amount of NOK 250 million.BerGenBio ASA has completed a Follow-on Equity Offering in the amount of NOK 250 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,750,000,000 Price\Range: NOK 0.1 Discount Per Security: NOK 0.012 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 750,000,000 Price\Range: NOK 0.1 Transaction Features: Rights Offering
お知らせ • May 10BerGenBio ASA to Report Q1, 2023 Results on Jun 22, 2023BerGenBio ASA announced that they will report Q1, 2023 results at 12:00 PM, Central European Standard Time on Jun 22, 2023
お知らせ • Dec 22+ 1 more updateBerGenBio ASA to Report Q4, 2023 Results on Feb 15, 2024BerGenBio ASA announced that they will report Q4, 2023 results on Feb 15, 2024